A Phase 2 interventional study of LY3561774 and Placebo in Dyslipidemias, Lipid Metabolism Disorders and Metabolic Diseases, sponsored by Eli Lilly and Company. Completed at 41 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.
35 studies on the registry are indexed under Hyperlipoproteinemias; 6 are open to participants now.
This study's enrollment of 205 is above the median of 84 across 29 interventional studies indexed under Hyperlipoproteinemias.
Browse Hyperlipoproteinemias studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Hyperlipoproteinemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have had within the past 3 months prior to screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 100 milligram (mg) LY3561774 subcutaneously (SC) on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.
Drug: LY3561774
Participants received 400 mg LY3561774 SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.
Drug: LY3561774
Participants received 800 mg LY3561774 SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.
Drug: LY3561774
Participants received placebo SC on Day 0 and Day 90 (-5 to +10 days). Follow up was continued until Day 360.
Drug: Placebo
Administered SC
Also known as: Solbinsiran
Administered SC
Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180
Change in apoB levels from baseline to Day 180 expressed as a percentage of the baseline levels. Least Square Mean (LS mean) using Mixed Model for Repeated Measures (MMRM) model adjusted for baseline.
Time frame: Baseline, Day 180
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180
Change in ANGPTL3 levels from baseline to Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 180
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180
Change in LDL-C levels from baseline to the day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 180
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 180
Change in HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 180
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180
Change in non-HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 180
Percent Change From Baseline for Triglycerides at Day 180
Change in triglycerides levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 180
Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3)
Change in ANGPTL3 levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 270
Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Change in non-HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 270
Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C)
Change in HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 270
Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)
Change in LDL-C levels from baseline to the day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 270
Percent Change From Baseline for Apolipoprotein B (ApoB)
Change in apoB levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS mean using MMRM model adjusted for baseline.
Time frame: Baseline, Day 270
Percent Change From Baseline for Triglycerides
Change in triglycerides levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
Time frame: Baseline, Day 270
Pharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY3561774
PK: Seady State AUC (0-∞) of LY3561774
Time frame: On Day 0: 0.5 hour (hr) and at the latest time after 2 hr post-dose, Day 90: 24 to 48 hr postdose
| Milestone | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Started | 58 | 30 | 58 | 59 |
| Received at least 1 dose of study drug | 57 | 30 | 58 | 59 |
| Completed | 57 | 27 | 55 | 54 |
| Not completed | 1 | 3 | 3 | 5 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 3 |
| Withdrew: Earthquake at the turkey site prevented participation in the study | 0 | 1 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
Change in apoB levels from baseline to Day 180 expressed as a percentage of the baseline levels. Least Square Mean (LS mean) using Mixed Model for Repeated Measures (MMRM) model adjusted for baseline.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 | -11.6 ± 3.65 | -14.1 ± 4.98 | -24.3 ± 3.10 | -19.0 ± 3.35 |
Change in ANGPTL3 levels from baseline to Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) at Day 180 | -3.2 ± 6.22 | -55.7 ± 4.01 | -70.8 ± 1.86 | -77.3 ± 1.46 |
Change in LDL-C levels from baseline to the day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) at Day 180 | -8.7 ± 3.87 | -9.9 ± 5.39 | -24.0 ± 3.21 | -19.7 ± 3.42 |
Change in HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) at Day 180 | 4.3 ± 2.59 | -2.1 ± 3.43 | -12.8 ± 2.15 | -19.4 ± 2.00 |
Change in non-HDL-C levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Day 180 | -10.2 ± 3.24 | -19.8 ± 4.06 | -33.1 ± 2.41 | -31.5 ± 2.47 |
Change in triglycerides levels from baseline to the Day 180 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Triglycerides at Day 180 | -15.1 ± 4.01 | -45.9 ± 3.61 | -57.8 ± 1.98 | -59.7 ± 1.90 |
Change in ANGPTL3 levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Angiopoietin-like Protein 3 (ANGPTL3) | -17.0 ± 6.00 | -49.0 ± 5.28 | -61.9 ± 2.75 | -69.8 ± 2.19 |
Change in non-HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) | -9.8 ± 3.22 | -13.5 ± 4.44 | -27.6 ± 2.56 | -27.3 ± 2.59 |
Change in HDL-C levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for High Density Lipoprotein-Cholesterol (HDL-C) | 1.5 ± 2.48 | -1.9 ± 3.48 | -7.3 ± 2.24 | -10.9 ± 2.18 |
Change in LDL-C levels from baseline to the day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Low Density Lipoprotein-Cholesterol (LDL-C) | -12.7 ± 3.78 | -7.1 ± 5.81 | -21.0 ± 3.39 | -17.5 ± 3.57 |
Change in apoB levels from baseline to Day 270 expressed as a percentage of the baseline levels. LS mean using MMRM model adjusted for baseline.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Apolipoprotein B (ApoB) | -9.5 ± 3.57 | -19.2 ± 4.61 | -19.7 ± 3.18 | -19.4 ± 3.20 |
Change in triglycerides levels from baseline to the Day 270 expressed as a percentage of the baseline levels. LS Mean from MMRM model adjusted for baseline and treatment.
| Percent change | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline for Triglycerides | -13.9 ± 4.63 | -38.3 ± 4.80 | -50.5 ± 2.63 | -52.5 ± 2.55 |
PK: Seady State AUC (0-∞) of LY3561774
| nanogram.hour per milliliter (ng*h/mL) | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|
| Pharmacokinetics (PK): Seady State Area Under the Concentration Curve From Hour 0 Extrapolated to Infinity (AUC 0-∞) of LY3561774 | 6979 ± 35 | 25045 ± 24 | 61306 ± 43 |
Collected over Baseline up to 360 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/57 (0%) | 5/57 (8.8%) | 16/57 (28.1%) |
| LY3561774 100 mg | 0/30 (0%) | 1/30 (3.3%) | 14/30 (46.7%) |
| LY3561774 400 mg | 0/58 (0%) | 3/58 (5.2%) | 14/58 (24.1%) |
| LY3561774 800 mg | 0/59 (0%) | 2/59 (3.4%) | 9/59 (15.3%) |
| Event | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 2/57 | 0/30 | 0/58 | 0/59 |
| CellulitisInfections and infestations | 0/57 | 1/30 | 0/58 | 0/59 |
| Angina pectorisCardiac disorders | 1/57 | 0/30 | 0/58 | 0/59 |
| PneumoniaInfections and infestations | 1/57 | 0/30 | 0/58 | 1/59 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/57 | 0/30 | 0/58 | 0/59 |
| Brain abscessInfections and infestations | 0/57 | 0/30 | 1/58 | 0/59 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/57 | 0/30 | 1/58 | 0/59 |
| Pelvic venous thrombosisVascular disorders | 0/57 | 0/30 | 1/58 | 0/59 |
| CholelithiasisHepatobiliary disorders | 0/57 | 0/30 | 0/58 | 1/59 |
| Pneumonia viralInfections and infestations | 0/57 | 0/30 | 0/58 | 1/59 |
| Event | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg |
|---|---|---|---|---|
| Covid-19Infections and infestations | 4/57 | 4/30 | 3/58 | 2/59 |
| GastroenteritisInfections and infestations | 3/57 | 3/30 | 2/58 | 0/59 |
| InfluenzaInfections and infestations | 0/57 | 2/30 | 2/58 | 2/59 |
| Pancreatic enzymes increasedInvestigations | 0/57 | 2/30 | 1/58 | 1/59 |
| HypertensionVascular disorders | 2/57 | 2/30 | 1/58 | 2/59 |
| NasopharyngitisInfections and infestations | 3/57 | 1/30 | 3/58 | 2/59 |
| Urinary tract infectionInfections and infestations | 3/57 | 1/30 | 1/58 | 1/59 |
| Lipase increasedInvestigations | 3/57 | 0/30 | 1/58 | 0/59 |
| Injection site reactionGeneral disorders | 0/57 | 1/30 | 3/58 | 1/59 |
All randomized participants
| Age, Continuous(years) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| Mean | 55.50 ± 11.61 | 58.40 ± 10.97 | 56.40 ± 11.97 | 57.30 ± 10.61 | 56.70 ± 11.30 |
| Sex: Female, Male(Participants) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| Female | 35 | 18 | 29 | 29 | 111 |
| Male | 23 | 12 | 29 | 30 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 36 | 20 | 39 | 44 | 139 |
| Not Hispanic or Latino | 22 | 8 | 19 | 15 | 64 |
| Unknown or Not Reported | 0 | 2 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 21 | 11 | 14 | 22 | 68 |
| Asian | 11 | 6 | 10 | 9 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 |
| White | 25 | 13 | 34 | 28 | 100 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| Argentina | 15 | 8 | 21 | 18 | 62 |
| Canada | 5 | 4 | 7 | 2 | 18 |
| Japan | 7 | 4 | 7 | 7 | 25 |
| Mexico | 21 | 12 | 18 | 26 | 77 |
| Poland | 3 | 0 | 1 | 1 | 5 |
| Turkey | 3 | 2 | 3 | 3 | 11 |
| United States | 4 | 0 | 1 | 2 | 7 |
| Baseline Apolipoprotein B (ApoB)(milligram per deciliter (mg/dL)) | Placebo | LY3561774 100 mg | LY3561774 400 mg | LY3561774 800 mg | Total |
|---|---|---|---|---|---|
| Median | 111 (23 to 246) | 109.50 (49 to 186) | 112 (73 to 169) | 114 (52 to 205) | 111 (23 to 246) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2022 to primary completion in Mar 2024, 19 months.
Results were first posted in Mar 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solbinsiran